Figure 4. Effects of temozolomide, AZD7762, or combined TMZ and AZD7762 on various proteins in the glioma cells. The T98G, U138MG, and U87MG glioma cells were treated with temozolomide (TMZ, 0.1 or 0.5 mM) and/or AZD7762 (0.25 μM) for 48 h. Then, the protein levels of p53, phospho-p53 (p-p53), BAX, extracellular signal-regulated kinase 1/2 (ERK 1/2), p-ERK 1/2, p38 mitogen-activated protein kinase (p38), p-p38 MAPK (p-p38), phosphatase and tensin homolog (PTEN), protein kinase B (AKT), p-AKT, signal transducer and activator of transcription 3 (STAT3), p-STAT3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were analyzed by western blotting using specific antibodies.